Among these loci, they identified the TrxR1gene and demonstrated that inhibiting TrxR1 with siRNA or AF, sensitized lung cancer cell lines resistant to MK2206 to treatment with this drug. This evidence concerns the gene TXNRD1 and lung cancer.